D. Reiss

发表

Dual orexin receptor antagonists show distinct effects on locomotor performance, ethanol interaction and sleep architecture relative to gamma-aminobutyric acid-A receptor modulators

Steven V. Fox, J. Uslaner, J. Renger, 2013, Front. Neurosci..

Progress in the development of oxytocin antagonists for use in preterm labor.

B. E. Evans, M. Bock, D. Reiss, 1995, Advances in experimental medicine and biology.

Selective alpha1a adrenergic receptor antagonists based on 4-aryl-3,4-dihydropyridine-2-ones.

J. Barrow, R. Freidinger, R. Chang, 2000, Bioorganic & medicinal chemistry letters.

A new class of bradykinin B1 receptor antagonists with high oral bioavailability and minimal PXR activity.

M. Bock, R. M. Dipardo, D. Reiss, 2008, Bioorganic & medicinal chemistry letters.

Discovery of [(2R,5R)‐5‐{[(5‐Fluoropyridin‐2‐yl)oxy]methyl}‐2‐methylpiperidin‐1‐yl][5‐methyl‐2‐(pyrimidin‐2‐yl)phenyl]methanone (MK‐6096): A Dual Orexin Receptor Antagonist with Potent Sleep‐Promoting Properties

Steven V. Fox, John D. Schreier, S. Doran, 2012, ChemMedChem.

A peripherally acting alpha-2 adrenoceptor antagonist: L-659,066.

V. J. Lotti, D. Reiss, J. Huff, 1988, The Journal of pharmacology and experimental therapeutics.

Discovery of 3,9-diazabicyclo[4.2.1]nonanes as potent dual orexin receptor antagonists with sleep-promoting activity in the rat.

John D. Schreier, S. Doran, G. McGaughey, 2010, Bioorganic & medicinal chemistry letters.

Proline bis-amides as potent dual orexin receptor antagonists.

J. Renger, P. Coleman, D. Reiss, 2008, Bioorganic & medicinal chemistry letters.

Pharmacological characterization and radioligand binding properties of a high-affinity, nonpeptide, bradykinin B1 receptor antagonist.

M. Bock, R. Freidinger, R. Chang, 2004, European journal of pharmacology.

L‐368,899, a potent orally active oxytocin antagonist for potential use in preterm labor

B. E. Evans, M. Kaufman, D. Veber, 1993 .

Discovery of a Pharmacologically Active Antagonist of the Two‐Pore‐Domain Potassium Channel K2P9.1 (TASK‐3)

Steven V. Fox, S. Doran, J. Renger, 2012, ChemMedChem.

Nonpeptide oxytocin antagonists: analogs of L-371,257 with improved potency.

B. E. Evans, M A Jacobson, M. Bock, 1999, Bioorganic & medicinal chemistry letters.

1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4- yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist.

D. Veber, R. Freidinger, D. Reiss, 1995, Journal of medicinal chemistry.

Synthesis and evaluation of a new series of Neuropeptide S receptor antagonists.

G. McGaughey, J. Renger, A. Gotter, 2010, Bioorganic & medicinal chemistry letters.

Discovery of 3-substituted aminocyclopentanes as potent and orally bioavailable NR2B subtype-selective NMDA antagonists.

A. Dilella, T. Mcdonald, D. Reiss, 2011, ACS chemical neuroscience.

In Vitro and in Vivo Evaluation of Dihydropyrimidinone C-5 Amides as Potent and Selective α1A Receptor Antagonists for the Treatment of Benign Prostatic Hyperplasia

J. Barrow, K. Rittle, R. Freidinger, 2000 .

Bradykinin B1 receptor antagonists: an alpha-hydroxy amide with an improved metabolism profile.

M. Bock, R. M. Dipardo, D. Reiss, 2008, Bioorganic & medicinal chemistry letters.

Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia.

John D. Schreier, S. Doran, G. McGaughey, 2010, Journal of medicinal chemistry.

Antagonism of T-type calcium channels inhibits high-fat diet-induced weight gain in mice.

S. Doran, J. Renger, J. Barrow, 2009, The Journal of clinical investigation.

Identification of an orally active, nonpeptidyl oxytocin antagonist.

B. E. Evans, D. Veber, R. Freidinger, 1993, The Journal of pharmacology and experimental therapeutics.

In vitro pharmacological profile of a novel structural class of oxytocin antagonists.

D. Veber, M. Bock, R. Freidinger, 1991, The Journal of pharmacology and experimental therapeutics.

Characterization of 5-hydroxytryptamine receptors in rat stomach fundus.

D. Reiss, D. Pettibone, B. Clineschmidt, 1985, The Journal of pharmacology and experimental therapeutics.

2-Aminobenzophenones as a novel class of bradykinin B1 receptor antagonists.

M. Bock, R. Freidinger, R. Chang, 2008, Journal of medicinal chemistry.

Potent bradykinin B1 receptor antagonists: 4-substituted phenyl cyclohexanes.

M. Bock, R. Freidinger, R. Chang, 2007, Bioorganic & medicinal chemistry letters.

Development of orally bioavailable and CNS penetrant biphenylaminocyclopropane carboxamide bradykinin B1 receptor antagonists.

M. Bock, R. M. Dipardo, D. Reiss, 2007, Journal of medicinal chemistry.

2,3-diaminopyridine bradykinin B1 receptor antagonists.

M. Bock, R. Freidinger, R. Chang, 2004, Journal of medicinal chemistry.

Generation and Characterization of a Human Bradykinin Receptor B1 Transgenic Rat as a Pharmacodynamic Model

M. Bock, R. M. Dipardo, R. Chang, 2004, Journal of Pharmacology and Experimental Therapeutics.

Indazole derivatives as novel bradykinin B1 receptor antagonists.

M. Bock, D. Reiss, S. Kuduk, 2010, Bioorganic & medicinal chemistry letters.

Bradykinin B1 antagonists: biphenyl SAR studies in the cyclopropanecarboxamide series.

M. Bock, R. M. Dipardo, D. Reiss, 2007, Bioorganic & medicinal chemistry letters.

2,3-Diaminopyridine as a platform for designing structurally unique nonpeptide bradykinin B1 receptor antagonists.

Dong-Mei Feng, Cuyue Tang, Christina Ng, 2005, Bioorganic & medicinal chemistry letters.

TASK-3 as a potential antidepressant target

Steven V. Fox, H. Meziane, S. Doran, 2011, Brain Research.

Promotion of Sleep by Suvorexant—A Novel Dual Orexin Receptor Antagonist

Steven V. Fox, S. Doran, J. Renger, 2011, Journal of neurogenetics.

Pharmacological characterization of MK-6096 – A dual orexin receptor antagonist for insomnia

Steven V. Fox, John D. Schreier, S. Doran, 2012, Neuropharmacology.

Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines.

S Vickers, R. Freidinger, D. Reiss, 1998, Journal of medicinal chemistry.

In vitro and in vivo evaluation of dihydropyrimidinone C-5 amides as potent and selective alpha(1A) receptor antagonists for the treatment of benign prostatic hyperplasia.

J. Barrow, K. Rittle, R. Freidinger, 2000, Journal of medicinal chemistry.

Orexin receptor antagonism prevents transcriptional and behavioral plasticity resulting from stimulant exposure

Steven V. Fox, Kenneth S. Koblan, Jason M. Uslaner, 2010, Neuropharmacology.

Discovery of 2,5-diarylnicotinamides as selective orexin-2 receptor antagonists (2-SORAs).

J. Renger, P. Coleman, S. Garson, 2013, Bioorganic & medicinal chemistry letters.

Antagonism of oxytocin in rats and pregnant rhesus monkeys by the novel cyclic hexapeptides, L-366,682 and L-366,948.

M. Bock, D. Reiss, M. Kaufman, 1991, The Journal of pharmacology and experimental therapeutics.

Quantitative Proteomics in Laser Capture Microdissected Sleep Nuclei From Rat Brain

Daniel S Spellman, J. Renger, P. Coleman, 2014, Journal of neurogenetics.

Discovery of a Pharmacologically Active Antagonist of the Two‐Pore‐Domain Potassium Channel K2P9.1 (TASK‐3)

Steven V. Fox, S. Doran, J. Renger, 2012, ChemMedChem.